Quantbot Technologies LP Acquires New Holdings in Caris Life Sciences, Inc. $CAI

Quantbot Technologies LP purchased a new stake in Caris Life Sciences, Inc. (NASDAQ:CAI) during the 2nd quarter, Holdings Channel reports. The firm purchased 19,675 shares of the company’s stock, valued at approximately $351,000.

Several other institutional investors have also recently modified their holdings of CAI. UBS Group AG lifted its stake in Caris Life Sciences by 825.9% in the 4th quarter. UBS Group AG now owns 2,183,980 shares of the company’s stock valued at $58,924,000 after buying an additional 1,948,107 shares in the last quarter. ProShare Advisors LLC purchased a new stake in shares of Caris Life Sciences in the fourth quarter valued at $336,000. Global Retirement Partners LLC boosted its stake in shares of Caris Life Sciences by 99,900.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after acquiring an additional 999 shares during the last quarter. Seven Grand Managers LLC boosted its stake in shares of Caris Life Sciences by 395.1% during the fourth quarter. Seven Grand Managers LLC now owns 495,095 shares of the company’s stock valued at $13,358,000 after acquiring an additional 395,095 shares during the last quarter. Finally, Norges Bank acquired a new position in Caris Life Sciences in the 4th quarter valued at about $2,976,000.

Analyst Ratings Changes

Several research firms have issued reports on CAI. JPMorgan Chase & Co. decreased their price target on shares of Caris Life Sciences from $35.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Wall Street Zen upgraded shares of Caris Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Wolfe Research cut shares of Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. Evercore reissued an “outperform” rating and set a $26.00 price target on shares of Caris Life Sciences in a research note on Thursday, August 6th. Finally, Weiss Ratings upgraded Caris Life Sciences from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, August 21st. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $26.33.

Caris Life Sciences Trading Down 2.8%

Shares of CAI stock opened at $25.63 on Friday. The firm’s 50-day simple moving average is $19.27 and its 200-day simple moving average is $18.72. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.53 and a quick ratio of 4.88. Caris Life Sciences, Inc. has a 1-year low of $14.19 and a 1-year high of $39.18. The firm has a market cap of $7.24 billion, a P/E ratio of 71.19 and a beta of 0.68.

Caris Life Sciences declared that its board has approved a share repurchase program on Monday, June 8th that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 2.1% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.